Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
3.965 EUR | +0.89% | +2.06% | -20.70% |
Apr. 03 | Valbiotis: launch of Valbiotis PRO Cholesterol in May | CF |
2023 | Valbiotis: capital increase successfully completed | CF |
Sales 2023 * | 6.17M 6.61M | Sales 2024 * | 8.4M 9M | Capitalization | 61.99M 66.4M |
---|---|---|---|---|---|
Net income 2023 * | -10M -10.71M | Net income 2024 * | -10M -10.71M | EV / Sales 2023 * | 6.84 x |
Net cash position 2023 * | 19.83M 21.25M | Net cash position 2024 * | 17.13M 18.35M | EV / Sales 2024 * | 5.34 x |
P/E ratio 2023 * |
-4.2
x | P/E ratio 2024 * |
-4.57
x | Employees | 48 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 91.48% |
1 day | +0.89% | ||
1 week | +2.06% | ||
Current month | +9.23% | ||
1 month | +12.64% | ||
3 months | -10.70% | ||
6 months | -26.30% | ||
Current year | -20.70% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | - | |
Frédéric Pelong
DFI | Director of Finance/CFO | 50 | 22-06-29 |
Jean Zetlaoui
CTO | Chief Tech/Sci/R&D Officer | - | 17-10-25 |
Members of the board | Title | Age | Since |
---|---|---|---|
Agnès Tixier
BRD | Director/Board Member | - | 19-03-17 |
Laurent Lévy
CHM | Chairman | 53 | 17-02-28 |
Chief Executive Officer | - | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 3.965 | +0.89% | 36 415 |
24-04-24 | 3.93 | +0.13% | 8,807 |
24-04-23 | 3.925 | +1.29% | 54,196 |
24-04-22 | 3.875 | +0.26% | 9,725 |
24-04-19 | 3.865 | -0.51% | 8,045 |
Real-time Euronext Paris, April 25, 2024 at 10:49 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-20.70% | 66.24M | |
-3.15% | 104B | |
+0.18% | 97.42B | |
+1.11% | 22.2B | |
-18.21% | 21.23B | |
-11.11% | 18.33B | |
-42.83% | 16.35B | |
-17.16% | 15.06B | |
+3.45% | 13.98B | |
+28.61% | 11.66B |
- Stock Market
- Equities
- ALVAL Stock